Proprietary CBD:TMP Cocrystal for Anxiety & Depression

ART12.11 is a proprietary cocrystalization of canibidiol (CBD) and tetramethylpyrazine (TMP; also called ligustrazine). Cocrystalization is a validated pharmaceutical method for overcoming problematic drug properties which allows for precise control over purity, potency, and consistency.

ART12.11 is protected under US Patent issued composition of matter and use until Dec 10, 2038 (with PCT national phase filings worldwide underway).

Cocrystalization to Improve CBD

  • CBD is known to exist in polymorphic states and has a low melting point, poor absorption and bioavailability (learn more about polymorphism)
  • ART12.11 offers the following advantages compared to CBD alone:
    • Bioavailability – ART12.11 delivers higher levels of CBD and its major metabolite CBD-7COOH
    • Adsorption – ART12.11 is more soluble in Fasted State Simulation Intestinal Fluid (FaSSIF) and Fed State Simulated Intestinal Fluid (FeSSIF)
    • Melting point – ART12.11 exhibits a single crystalline melt and higher melting point (91oC) than either individual component (CBD 65oC)

Can Anxiety Treatments be Improved?

Anxiety is the most common mental health condition in the US, with a prevalence of 40 million adults and incidence of ~19% of the adult population each year.** Anxiety disorders include generalized anxiety disorder (GAD), panic disorder, social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD), among others.  The wordwide market in anxiety was $11B in 2021 and expected to reach $16.25B by 2029.Ŧ

Most commonly used drugs are suboptimal with issues of slow onset, dependance and drug interactions leaving many unmet needs.

 **Anxiety and Depression Association of America (ADAA); ŦDataBridge Market Research, Global Anxiety Disorder Market report

Preclinical results

Data presented at Annual Symposium of the International Cannabinoid Research Society, 2023.